Engineered exosomes for CRISPR/Cas delivery to overcome oncogene-driven drug resistance.
The goal of this review is to outline a realistic pathway featuring proof-of-concept research, through discoveries to the creation of manufacturable, safe, and effective exosome/CRISPR therapeutics that can trigger durable therapeutic responses in resistant malignancies.